Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly Docetaxel and Trastuzumab in HER2+ Metastatic Breast Cancer
NCT00006104Phase 2Completed
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- Sep 1998
- Primary completion
- Jul 2003
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab in breast cancer, sponsored by Vanderbilt-Ingram Cancer Center. Primary endpoint: Objective Response Rate. Started Sep 1998; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00006104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006104.